Taltz Patent Protection
6 patents · Eli Lilly and Company
F
Patent Strength
33/100
6
Total Patents
1
Assignees
2027
Earliest Expiration
2042
Latest Expiration
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005713 | Recombinant analog protein with configurable activity | Eli Lilly and Company | Nov 5, 2009 | Nov 4, 2027 | 22 | 1.6y left |
| 10005714 | Therapeutic agent with advanced CMOS mechanism | Eli Lilly and Company | May 12, 2012 | Oct 28, 2028 | 14 | 2.6y left |
| 10005715 | Method for enhanced neural genetic modification | Eli Lilly and Company | Jul 5, 2026 | Sep 14, 2042 | 26 | 16.4y left |
| 10005716 | Novel adaptive nano-scale compound and synthesis thereof | Eli Lilly and Company | Sep 20, 2026 | Mar 9, 2042 | 20 | 15.9y left |
| 10005717 | Therapeutic agent with high-performance AI-driven mechanism | Eli Lilly and Company | Apr 27, 2017 | Apr 15, 2034 | 39 | 8.0y left |
| 10005718 | Medical device for optimized nano-scale delivery | Eli Lilly and Company | May 4, 2013 | May 23, 2031 | 21 | 5.1y left |